Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $158

Benzinga Newsdesk www.benzinga.com Negative 77.2%

Neg 77.2% Neu 0% Pos 0%

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $171 to $158.